An observational study in Nephrotoxicity, sponsored by University Hospital, Geneva. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-09.
Sponsored by University Hospital, Geneva · Observational
The aim of the present study is to determine whether a high dose of intravenous NAC is efficient in preventing CN after emergency contrast injection in patients with renal failure.
Prevention of acute kidney injury (AKI) post contrast injection remains mandatory given its association to morbidity and mortality1.
Contrast nephropathy (CN) was classically defined as an increase in 25% or more or absolute increase of 44 umol/l of creatinine levels within three days following contrast injection2. Markers such as cystatine C may be more sensitive to identify CN and also to correlate to mortality8 although a definition of CN using these markers is lacking.
In patients undergoing elective radiological procedures, CN can be prevented by hydration, withdrawal of diuretics and nephrotoxic drugs. N Acetylcysteine (NAC) has been proposed to protect against contrast nephropathy since 200013. While hydratation is clearly beneficial in preventing CIN14, the role of NAC administration is still uncertain and results of RCTs gave conflicting results regarding its effect15.
Intravenous N-acetylcysteine (NAC) may be the form of choice in emergency procedures given its rapid disponibility and its ease of administration in patients whose consciousness is altered or who can not eat.
The aim of the present study is therefore to determine whether 6000 mg of intravenous NAC is efficient in preventing CN after emergency contrast injection in CKD patients.
Inclusion criteria:
One hundred and thirty consecutive patients with an estimated GFR \< 60 mL/min and an indication to undergo an emergent contrast-enhanced CT will be included in the study. Exclusion criteria: asthma, pregnancy, obstructive nephropathy and patient or family's refusal.
Patients will be blindly randomized by computer to either placebo (0.45% saline) or high dose (6000 mg) iv n-acétylcystéine (flumicil) iv diluted in 0.45% saline. All patients will receive intravenous hydration (250 ml NaCl 0.45% at least) before the CT scan and 1000 ml after the examination depending on clinical possibilities.
Creatinine and cystatine C serum levels will be collected one hour before CT scan and at day 2, 4 and 10. The T0 value will be the value measured before the CT-scan and not the baseline admission value in order to correct for differential hydratation due to different waiting time and hydratation before tomography. Serum Creatinine and Cystatine C will be measured by the Jaffe method, and by a nephelometric assay respectively.
Outcome measures:
The primary endpoint of the study will be the occurrence of contrast nephropathy at day 2, 4 or 10, defined as an increase of at least 25% and/or 44 umol/l in serum creatinine level or cystatine C levels at day 2, 4 or 10 compared to day 0. We will also assess the proportion of patients with contrast nephropathy regarding the biomarker used and according to AKIN criteria as well. D The AKIN criteria defined a stage 1 AKI as an increase in creatinine between 150% and 199% from baseline or an absolute increase of at least 26.2 umol/l, a stage 2 AKI as an increase between 200% and 299% from baseline and a stage 3 AKI as an increase of at least 300% from baseline or a creatinine concentration higher than 354 umol/l with an acute rise of at least 44 umol/l or initiation of RRT.
Secondary endpoints will be the mean increases in creatinine and cystatin C concentrations in days 2, 4 and 10 and the maximum increase during the time periods from day 2 to day 10 (peak increase).
University Hospital, Geneva is the lead sponsor of 378 studies on the registry; 69 are open to participants now.
Counted across the registry records on this site, refreshed daily.
emergency center patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
occurrence of contrast nephropathy at day 2, 4 or 10, which was defined as an increase of at least 25% and/or 44 umol/l in serum creatinine level or cystatine C levels at day 2, 4 or 10 compared to day 0.
Time frame: 10 days
mean increases in creatinine and cystatin C concentrations on days 2, 4 and 10 and maximum increase during the time periods from day 2 to day 10 (peak increase).
Time frame: 10 days
No study locations are listed for this record.
The record gives a start of May 2008, a primary completion of Nov 2010 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.